Mogamulizumab-kpkc

Class: Antineoplastic Agents
- CC Chemokine Receptor 4 Antagonist
- CCR4 Inhibitor
Chemical Name: Anti-(human programmed CC chemokine receptor type 4) (human-mouse monoclonal KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 k-chain immunoglobulin G1 dimer
Molecular Formula: C₆₅₂₀H₁₀₀₇₂N₁₇₃₆O₂₀₂₀S₄₂
CAS Number: 1159266-37-1
Brands: Poteligeo

Medically reviewed by Drugs.com on Feb 28, 2022. Written by ASHP.

Introduction

Antineoplastic agent; recombinant humanized anti-CC chemokine receptor 4 (anti-CCR4) monoclonal antibody.

Uses for Mogamulizumab-kpkc

Cutaneous T-cell Lymphoma (CTCL)

Mycosis Fungoides or Sézary Syndrome

Treatment of relapsed or refractory mycosis fungoides or Sézary syndrome that has progressed following at least 1 prior systemic therapy. Efficacy based on substantially prolonged progression-free survival and improved overall response rates compared with vorinostat.

Designated an orphan drug by FDA for treatment of cutaneous T-cell lymphoma.

Mogamulizumab-kpkc Dosage and Administration

General

• Because of the risk of infusion-related reactions, a premedication regimen (e.g., acetaminophen and diphenhydramine) is recommended prior to the initial mogamulizumab infusion. If an infusion-related reaction occurs, administer premedication prior to subsequent infusions.

Administration

IV Administration

For solution compatibility information, see Compatibility under Stability.

Administer by IV infusion. Do not administer by sub-Q injection or rapid IV administration.

Dilute mogamulizumab-kpkc injection to an appropriate concentration (see Dilution under Dosage and Administration) prior to IV infusion. (See Storage under Stability.)

Administer using a sterile, low-protein-binding 0.22-µm (or equivalent) inline filter.

Do not mix with or administer simultaneously through the same IV line with other drugs.

Dilution

Withdraw appropriate dose of mogamulizumab-kpkc injection containing 4 mg/mL from appropriate number of vials and inject into a PVC or polyolefin infusion bag containing an appropriate volume of 0.9% sodium chloride injection to achieve a final concentration of 0.1–3 mg/mL.

Mix the diluted solution by gentle inversion; do not shake.

Immediate administration recommended. If necessary, may refrigerate diluted solution for ≤4 hours. (See Storage under Stability.)

Discard any partially used vials or diluted solution.

Rate of Administration

Administer by IV infusion over ≥60 minutes.

Dosage

Adults

Mycosis Fungoides or Sézary Syndrome

IV

Cycle 1: 1 mg/kg administered on days 1, 8, 15, and 22 of a 28-day cycle.

Subsequent cycles: 1 mg/kg on days 1 and 15 of each 28-day cycle.

Continue therapy until disease progression or unacceptable toxicity occurs.

May administer within 2 days of scheduled dose. If a dose is missed, administer as soon as possible and then resume dosing schedule.